Jacobio Pharmaceuticals
China - Beijing
PharmaceuticalFocus: Small Molecules?
Jacobio Pharmaceuticals is a life sciences company focused on Small Molecules?.
OncologyNeurology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
JAB-3312
Non-small Cell Lung CancerClinical Trials (1)
NCT04045496A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Phase 1JAB-8263
Solid Tumors, AdultClinical Trials (1)
NCT04587479A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Phase 1JAB-3068
Non-small Cell Lung CancerClinical Trials (1)
NCT03518554A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Phase 1JAB-2485
Solid TumorsClinical Trials (1)
NCT05490472JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Phase 1/2JAB-3068
Non-small Cell Lung CancerClinical Trials (1)
NCT03565003A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Phase 1/2JAB-3068
Advanced Solid TumorJAB-8263
NSCLCClinical Trials (1)
NCT04686682A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Phase 1/2JAB-BX102
Solid TumorJAB-30355
Solid TumorsClinical Trials (1)
NCT06386146JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Phase 1/2JAB-23E73
Advanced Solid TumorsClinical Trials (1)
NCT06973564JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/2JAB-21822
Advanced Solid TumorClinical Trials (1)
NCT05002270JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Phase 1/2JAB-23E73
Advanced Solid TumorClinical Trials (1)
NCT06959615A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 10 clinical trials